Premium
CD34 + cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients
Author(s) -
Ringhoffer Mark,
Wiesneth Markus,
Harsdorf Stephanie,
Schlenk Richard F.,
Schmitt Anita,
Reinhardt Peter P.,
Moessner Margit,
Grimminger Wolfgang,
Mertens Thomas,
Reske Sven N.,
Döhner Hartmut,
Bunjes Donald
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05062.x
Subject(s) - medicine , cumulative incidence , transplantation , cd34 , graft versus host disease , surgery , minimal residual disease , incidence (geometry) , gastroenterology , stem cell , leukemia , biology , physics , optics , genetics
Summary The present study investigated the effects of CD34 + cell selection in 102 patients using the CliniMACS device. Patients were at high risk for the development of graft versus host disease (GvHD) because of age, or the use of a haploidentical, mismatched or unrelated donor (UD). The median age of the patients was 44 years. The CliniMACS procedure yielded 8·0 × 10 6 CD34 + cells/kg and the number of residual T cells was 1·3 × 10 4 /kg (median). The median follow up was 20·6 months. The probability of graft failure was 7%. The rate of acute GvHD was low (compatible family donors 10%, UDs 17%, and haploidentical donors 26%) with no patient enduring more than grade II disease. The cumulative incidence of chronic GvHD at the median follow up after transplant was 15% for the compatible family donor group, 40% for the UD group and 78% in the group transplanted from a haploidentical donor Treatment failure was mainly because of transplant‐related mortality, especially aspergillus infection, and not due to relapse. The probability of disease‐free survival, stratified for the risk of treatment failure, was 27% for the high risk, 46% for the intermediate risk and 83% for the low risk group.